Ansixinta Minjuvi® (Tafasitamab) oo lagu daray Lenalidomide si loogu daaweeyo Bukaannada Qaangaarka ah ee qaba Lymphoma-ka Unugga B-B ee Dib-u-dhacay ama Ka-baxsan ee Shiinaha

Maajo 21, 2025, InnoCare Pharma waxay ku dhawaaqday in Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) uu oggolaaday Minjuvi® (tafasitamab), oo ah unug bini'aadam ah oo Fc-modified cytolytic CD19 ah oo bartilmaameedsanaya monoclonal antibody, oo lagu daray lenalidomide, oo ay ku xigto Minjuvi monotherapy, si loogu daaweeyo bukaanada qaangaarka ah ee qaba lymphoma-ka unugyada B ee soo noqnoqda ama soo noqnoqda (DLBCL) kuwaas oo aan u qalmin tallaalka unugyada asliga ah ee autologous (ASCT). Kani waa unug-difaaca CD19 ee ugu horreeyay ee loo ansixiyo daaweynta DLBCL ee soo noqnoqda ama soo noqnoqda ee Shiinaha.

Ku saabsan Tafasitamab

Tafasitamab waa unug difaaca jirka ee Fc-modified cytolytic CD19 oo bartilmaameedsanaya monoclonal antibody. Tafasitamab waxay ku daraysaa domain Fc ah oo la habeeyay, kaas oo dhexdhexaadiya lysis-ka unugyada B iyada oo loo marayo apoptosis iyo habka wax ka qabashada difaaca jirka oo ay ku jiraan sunta ka hortagga unugyada ee ku tiirsan Antibody-body-mediated Cytotoxicity (ADCC) iyo Antibody-Dependent Cellular Phagocytosis (ADCP).

MorphoSys iyo Incyte waxay galeen: (a) bishii Janaayo 2020, heshiis iskaashi iyo shati ah si loo horumariyo loona suuq geeyo tafasitamab adduunka oo dhan; iyo (b) bishii Febraayo 2024, heshiis kaas oo Incyte ay ku heshay xuquuq gaar ah oo ay ku horumarin karto oo ay ku ganacsan karto tafasitamab adduunka oo dhan.

Bishii Agoosto 2021, Incyte waxay heshiis iskaashi iyo shati la gashay InnoCare si loogu horumariyo loona suuq geeyo tafasitamab gaar ah oo ku saabsan dhiig-karka iyo kansarka ee Shiinaha Weyn.

Dalka Mareykanka, Monjuvi (tafasitamab-cxix) waxay heshay oggolaansho degdeg ah oo ka timid Maamulka Cuntada iyo Dawooyinka ee Mareykanka iyadoo lala kaashanayo lenalidomide si loogu daaweeyo bukaanada qaangaarka ah ee qaba DLBCL oo soo noqnoqda ama aan si kale loo cayimin, oo ay ku jiraan DLBCL oo ka dhasha lymphoma-ka heerka hoose, iyo kuwa aan u qalmin tallaalka unugyada asliga ah ee autologous (ASCT). Yurub, Minjuvi (tafasitamab) waxay heshay Oggolaansho Suuqgeyn shuruudaysan oo ka timid Hay'adda Daawooyinka Yurub iyadoo lala kaashanayo lenalidomide, oo ay ku xigto daaweynta Minjuvi monotherapy, si loogu daaweeyo bukaanada qaangaarka ah ee qaba lymphoma-ka B-cell ee soo noqnoqda ama soo noqnoqda (DLBCL) ee aan u qalmin tallaalka unugyada asliga ah ee autologous (ASCT).

Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.

Lambarka Taleefanka: 4008803716

Email：myimmnet@163.com